Novel insights into chk1 regulation by phosphorylation

Cell Structure and Function

Volumn 40, Issue 1, 2014, Pages 43-50

  Goto, Hidemasa ^a,b   Kasahara, Kousuke ^a,c   Inagaki, Masaki ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Cell cycle checkpoint; Chk1; Phosphorylation

Indexed keywords

ATR PROTEIN; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; EXPORTIN 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN 14 3 3; PROTEIN TYROSINE PHOSPHATASE; REPLICATION FACTOR A; SERINE; SINGLE STRANDED DNA; UBIQUITIN PROTEIN LIGASE E3; ATM PROTEIN; CYCLIN DEPENDENT KINASE; PROTEIN KINASE;

ARTICLE; AUTOPHOSPHORYLATION; BINDING KINETICS; CELL CYCLE REGULATION; COMPLEX FORMATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME PHOSPHORYLATION; ENZYME REGULATION; NUCLEAR EXPORT SIGNAL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; ANIMAL; CHEMISTRY; HUMAN; METABOLISM; PHOSPHORYLATION;

ANIMALS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CYCLIN-DEPENDENT KINASES; HUMANS; PHOSPHORYLATION; PROTEIN KINASES; SERINE;

EID: 84923207327     PISSN: 03867196     EISSN: 13473700     Source Type: Journal    
DOI: 10.1247/csf.14017     Document Type: Article

References (89)

1. Antoni, L., Sodha, N., Collins, I., and Garrett, M.D. 2007. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat. Rev. Cancer, 7: 925-936.
2. Appella, E. and Anderson, C.W. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem., 268: 2764-2772.
3. Bekker-Jensen, S., Lukas, C., Kitagawa, R., Melander, F., Kastan, M.B., Bartek, J., and Lukas, J. 2006. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J. Cell Biol., 173: 195-206.
4. Biggins, S., Palermo, C., Hope, J.C., Freyer, G.A., Rao, H., and Walworth, N.C. 2008. Importance of a C-Terminal Conserved Region of Chk1 for Checkpoint Function. PLoS ONE, 3: 1427.
5. Boutros, R., Lobjois, V., and Ducommun, B. 2007. CDC25 phosphatases in cancer cells: key players? Good targets? Nat. Rev. Cancer, 7: 495-507.
6. Brown, E.J. and Baltimore, D. 2000. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev., 14: 397-402
7. Bulavin, D.V., Higashimoto, Y., Popoff, I.J., Gaarde, W.A., Basrur, V., Potapova, O., Appella, E., and Fornace, A.J., Jr. 2001. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature, 411: 102-107.
8. Busino, L., Chiesa, M., Draetta, G.F., and Donzelli, M. 2004. Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene, 23: 2050-2056.
9. Caparelli, M.L. and O’Connell, M.J. 2013. Regulatory motifs in Chk1. Cell Cycle, 12: 916-922.
10. Capasso, H., Palermo, C., Wan, S., Rao, H., John, U.P., O’Connell, M.J., and Walworth, N.C. 2002. Phosphorylation activates Chk1 and is required for checkpoint-mediated cell cycle arrest. J. Cell Sci., 115(23): 4555-4564.
11. Carrassa, L. and Damia, G. 2011. Unleashing Chk1 in cancer therapy. Cell Cycle, 10: 2121-2128.
12. Chen, M.S., Ryan, C.E., and Piwnica-Worms, H. 2003. Chk1 Kinase Negatively Regulates Mitotic Function of Cdc25A Phosphatase through 14-3-3 Binding. Mol. Cell. Biol., 23: 7488-7497.
13. Chen, P., Luo, C., Deng, Y, Ryan, K., Register, J., Margosiak, S., Tempczyk-Russell, A., Nguyen, B., Myers, P., Lundgren, K., And others. 2000. The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell, 100: 681-692.
14. Chini, C.C. and Chen, J. 2004. Claspin, a regulator of Chk1 in DNA replication stress pathway. DNA Repair (Amst), 3: 1033-1037.
15. Ciccia, A. and Elledge, S.J. 2010. The DNA damage response: making it safe to play with knives. Mol. Cell, 40: 179-204.
16. Cimprich, K.A. and Cortez, D. 2008. ATR: An essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol., 9: 616-627.
17. Clarke, C.A. and Clarke, P.R. 2005. DNA-dependent phosphorylation of Chk1 and Claspin in a human cell-free system. Biochem. J., 388(2): 705-712.
18. Cremona, C.A. and Behrens, A. 2014. ATM signalling and cancer. Oncogene, 33: 3351-3360.
19. Dai, Y. and Grant, S. 2010. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res., 16: 376383.
20. de Klein, A., Muijtjens, M., van Os, R., Verhoeven, Y., Smit, B., Carr, A.M., Lehmann, A.R., and Hoeijmakers, J.H. 2000. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr. Biol., 10: 479-482.
21. Enomoto, M., Goto, H., Tomono, Y., Kasahara, K., Tsujimura, K., Kiyono, T., and Inagaki, M. 2009. Novel positive feedback loop between Cdk1 and Chk1 in the nucleus during G2/M transition. J. Biol. Chem., 284: 34223-34230.
22. Flynn, R.L. and Zou, L. 2011. ATR: A master conductor of cellular responses to DNA replication stress. Trends Biochem. Sci., 36: 133140.
23. Goto, H., Izawa, I., Li, P., and Inagaki, M. 2012. Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anticancer therapy? Cancer Sci., 103: 1195-1200.
24. Henry, M.K., Lynch, J.T., Eapen, A.K., and Quelle, F.W. 2001. DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway. Blood, 98: 834841.
25. Honaker, Y. and Piwnica-Worms, H. 2010. Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction. Oncogene, 29: 3324-3334.
26. Huh, J. and Piwnica-Worms, H. 2013. CRL4(CDT2) targets CHK1 for PCNA-independent destruction. Mol. Cell. Biol., 33: 213-226.
27. Ikegami, Y., Goto, H., Kiyono, T., Enomoto, M., Kasahara, K., Tomono, Y., Tozawa, K., Morita, A., Kohri, K., and Inagaki, M. 2008. Chk1 phosphorylation at Ser286 and Ser301 occurs with both stalled DNA replication and damage checkpoint stimulation. Biochem. Biophys. Res. Commun., 377: 1227-1231.
28. Jackman, M., Lindon, C., Nigg, E.A., and Pines, J. 2003. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat. Cell Biol., 5: 143-148.
29. Jackson, S.P. and Bartek, J. 2009. The DNA-damage response in human biology and disease. Nature, 461: 1071-1078.
30. Jiang, K., Pereira, E., Maxfield, M., Russell, B., Goudelock, D.M., and Sanchez, Y. 2003. Regulation of Chk1 includes chromatin association and 14-3-3 binding following phosphorylation on Ser-345. J. Biol. Chem., 278: 25207-25217.
31. Jin, J., Shirogane, T., Xu, L., Nalepa, G., Qin, J., Elledge, S.J., and Harper, J.W. 2003. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev., 17: 3062-3074.
32. Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J.F., Wyczalkowski, M.A., And others. 2013. Mutational landscape and significance across 12 major cancer types. Nature, 502: 333-339.
33. Kasahara, K., Goto, H., Enomoto, M., Tomono, Y., Kiyono, T., and Inagaki, M. 2010. 14-3-3gamma mediates Cdc25A proteolysis to block premature mitotic entry after DNA damage. EMBO J., 29: 2802-2812.
34. Katsuragi, Y. and Sagata, N. 2004. Regulation of Chk1 kinase by autoinhibition and ATR-mediated phosphorylation. Mol. Biol. Cell, 15: 16801689.
35. King, F.W., Skeen, J., Hay, N., and Shtivelman, E. 2004. Inhibition of Chk1 by activated PKB/Akt. Cell Cycle, 3: 634-637.
36. Kosoy, A. and O’Connell, M.J. 2008. Regulation of Chk1 by its C- terminal domain. Mol. Biol. Cell, 19: 4546-4553.
37. Kramer, A., Mailand, N., Lukas, C., Syljuasen, R.G., Wilkinson, C.J., Nigg, E.A., Bartek, J., and Lukas, J. 2004. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat. Cell Biol., 6: 884-891.
38. Kumagai, A. and Dunphy, W.G. 2000. Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. Mol. Cell, 6: 839-849.
39. Kumagai, A., Kim, S.M., and Dunphy, W.G. 2004. Claspin and the activated form of ATR-ATRIP collaborate in the activation of Chk1. J. Biol. Chem., 279: 49599-49608.
40. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S., and Getz SA., 2014. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 505: 495-501.
41. Leung-Pineda, V., Ryan, C.E., and Piwnica-Worms, H. 2006. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol. Cell. Biol., 26: 7529-7538.
42. Leung-Pineda, V., Huh, J., and Piwnica-Worms, H. 2009. DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res., 69: 2630-2637.
43. Li, P., Goto, H., Kasahara, K., Matsuyama, M., Wang, Z., Yatabe, Y., Kiyono, T., and Inagaki, M. 2012. P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation. Mol. Biol. Cell, 23: 1582-1592.
44. Liu, Q., Guntuku, S., Cui, X.S., Matsuoka, S., Cortez, D., Tamai, K., Luo SA, Carattini-Rivera, S., De Mayo, F., Bradley, A., And others. 2000. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev., 14: 1448-1459.
45. Lu, X., Nannenga, B., and Donehower, L.A. 2005. PPM1D dephosphory- lates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev., 19: 1162-1174.
46. Lukas, C., Falck, J., Bartkova, J., Bartek, J., and Lukas, J. 2003. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat. Cell Biol., 5: 255-260.
47. Ma, C.X., Janetka, J.W., and Piwnica-Worms, H. 2011. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol. Med., 17: 88-96.
48. Manke, I.A., Nguyen, A., Lim, D., Stewart, M.Q., Elia, A.E., and Yaffe, M.B. 2005. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol. Cell, 17: 37-38.
49. Matsuyama, M., Goto, H., Kasahara, K., Kawakami, Y., Nakanishi, M., Kiyono, T., Goshima, N., and Inagaki, M. 2011. Nuclear Chk1 prevents premature mitotic entry. J. Cell Sci., 124(13): 2113-2119.
50. Maugeri-Sacca, M., Bartucci, M., and De Maria, R. 2013. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treat. Rev., 39: 525-533.
51. Maya-Mendoza, A., Petermann, E., Gillespie, D.A., Caldecott, K.W., and Jackson, D.A. 2007. Chk1 regulates the density of active replication origins during the vertebrate S phase. EMBO J., 26: 2719-2731.
52. McGowan, C.H. 2002. Checking in on Cds1 (Chk2): A checkpoint kinase and tumor suppressor. Bioessays, 24: 502-511.
53. Melixetian, M., Klein, D.K., Sorensen, C.S., and Helin, K. 2009. NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint. Nat. Cell Biol., 11: 1247-1253.
54. Mohammad, D.H. and Yaffe, M.B. 2009. 14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response. DNA Repair (Amst), 8: 1009-1017.
55. Neely, K.E. and Piwnica-Worms, H. 2003. Cdc25A regulation: to destroy or not to destroy--is that the only question? Cell Cycle, 2: 455-457.
56. Niida, H., Katsuno, Y, Banerjee, B., Hande, M.P, and Nakanishi, M. 2007. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol. Cell. Biol., 27: 2572-2581.
57. Nimbalkar, D. and Quelle, F.W. 2008. Phosphoinositide 3-kinase signaling overrides a G2 phase arrest checkpoint and promotes aberrant cell cycling and death of hematopoietic cells after DNA damage. Cell Cycle, 7: 2877-2885.
58. Polager, S. and Ginsberg, D. 2009. P53 and E2f: partners in life and death. Nat. Rev. Cancer, 9: 738-748.
59. Puc, J., Keniry, M., Li, H.S., Pandita, T.K., Choudhury, A.D., Memeo, L., Mansukhani, M., Murty, V.V., Gaciong, Z., Meek, S.E., And others. 2005. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell, 7: 193-204.
60. Raman, M., Earnest, S., Zhang, K., Zhao, Y., and Cobb, M.H. 2007. TAO kinases mediate activation of p38 in response to DNA damage. EMBO J., 26: 2005-2014.
61. Reinhardt, H.C., Aslanian, A.S., Lees, J.A., and Yaffe, M.B. 2007. P53- Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA Damage. Cancer Cell, 11: 175-189.
62. Reinhardt, H.C. and Yaffe, M.B. 2009. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr. Opin. Cell Biol., 21: 245-255.
63. Reinhardt, H.C., Hasskamp, P., Schmedding, I., Morandell, S., van Vugt, M.A., Wang, X., Linding, R., Ong, S.E., Weaver, D., Carr, S.A., And others. 2010. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol. Cell, 40: 34-49.
64. Rhind, N. and Russell, P. 2000. Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways. J. Cell Sci., 113(22): 3889-3896.
65. Riley, T., Sontag, E., Chen, P, and Levine, A. 2008. Transcriptional control of human p53-regulated genes. Nat Rev Mol. Cell Biol., 9: 402-412.
66. Sanchez, Y., Wong, C., Thoma, R.S., Richman, R., Wu, Z., Piwnica- Worms, H., and Elledge, S.J. 1997. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science, 277: 1497-1501.
67. Shiloh, Y. and Ziv, Y. 2013. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol., 14: 197-210.
68. Shimada, M., Niida, H., Zineldeen, D.H., Tagami, H., Tanaka, M., Saito SA, and Nakanishi, M. 2008. Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell, 132: 221-232.
69. Shiromizu, T., Goto, H., Tomono, Y., Bartek, J., Totsukawa, G., Inoko, A., Nakanishi, M., Matsumura, F., and Inagaki, M. 2006. Regulation of mitotic function of Chk1 through phosphorylation at novel sites by cyclin-dependent kinase 1 (Cdk1). Genes Cells, 11: 477-485.
70. Shtivelman, E., Sussman, J., and Stokoe, D. 2002. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr. Biol., 12: 919-924.
71. Smits, V.A., Reaper, P.M., and Jackson, S.P 2006. Rapid PIKK-dependent release of Chk1 from chromatin promotes the DNA-damage checkpoint response. Curr. Biol., 16: 150-159.
72. Syljuasen, R.G., Sorensen, C.S., Hansen, L.T., Fugger, K., Lundin, C., Johansson, F., Helleday, T., Sehested, M., Lukas, J., and Bartek, J. 2005. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell. Biol., 25: 3553-3562.
73. Takai, H., Tominaga, K., Motoyama, N., Minamishima, Y.A., Nagahama SA, Tsukiyama, T., Ikeda, K., Nakayama, K., Nakanishi, M., and Nakayama, K. 2000. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev., 14: 1439-1447.
74. Thompson, R. and Eastman, A. 2013. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design. Br. J. Clin. Pharmacol., 76: 358-369.
75. Tibelius, A., Marhold, J., Zentgraf, H., Heilig, C.E., Neitzel, H., Ducommun, B., Rauch, A., Ho, A.D., Bartek, J., and Kramer, A. 2009. Microcephalin and pericentrin regulate mitotic entry via centrosome- associated Chk1. J. Cell Biol., 185: 1149-1157.
76. Tonic, I., Yu, W.N., Park, Y., Chen, C.C., and Hay, N. 2010. Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci. J. Biol. Chem., 285: 23790-23798.
77. Vandin, F., Upfal, E., and Raphael, B.J. 2012. De novo discovery of mutated driver pathways in cancer. Genome Res., 22: 375-385.
78. Wade, M., Li, Y.C., and Wahl, G.M. 2013. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer, 13: 83-96.
79. Walker, M., Black, E.J., Oehler, V., Gillespie, D.A., and Scott, M.T. 2009. Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity. Oncogene, 28: 2314-2323.
80. Wang, J., Han, X., Feng, X., Wang, Z., and Zhang, Y. 2012. Coupling cellular localization and function of checkpoint kinase 1 (Chk1) in checkpoints and cell viability. J. Biol. Chem., 287: 25501-25509.
81. Wilsker, D., Petermann, E., Helleday, T., and Bunz, F. 2008. Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc. Natl. Acad. Sci. USA, 105: 20752-20757.
82. Xu, N., Hegarat, N., Black, E.J., Scott, M.T., Hochegger, H., and Gillespie, D.A. 2010. Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. J. Cell Biol., 190: 297-305.
83. Xu, N., Libertini, S., Zhang, Y., and Gillespie, D.A. 2011. Cdk phosphorylation of Chk1 regulates efficient Chk1 activation and multiple checkpoint proficiency. Biochem. Biophys. Res. Commun., 413: 465-470.
84. Xu, N., Libertini, S., Black, E.J., Lao, Y., Hegarat, N., Walker, M., and Gillespie, D.A. 2012. Cdk-mediated phosphorylation of Chk1 is required for efficient activation and full checkpoint proficiency in response to DNA damage. Oncogene, 31: 1086-1094.
85. Zeman, M.K. and Cimprich, K.A. 2014. Causes and consequences of replication stress. Nat. Cell Biol., 16: 2-9.
86. Zhang, Y. and Hunter, T. 2014. Roles of Chk1 in cell biology and cancer therapy. Int. J. Cancer, 134: 1013-1023.
87. Zhang, Y.W., Otterness, D.M., Chiang, G.G., Xie, W., Liu, Y.C., Mercurio, F., and Abraham, R.T. 2005. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol. Cell, 19: 607618.
88. Zhang, Y.W., Brognard, J., Coughlin, C., You, Z., Dolled-Filhart, M., Aslanian, A., Manning, G., Abraham, R.T., and Hunter, T. 2009. The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol. Cell, 35: 442-453.
89. Zhao, H. and Piwnica-Worms, H. 2001. A TR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol., 21: 4129-4139.